Rep. Gilbert Ray Cisneros, Jr. Sells Boston Scientific Corporation (NYSE:BSX) Shares

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on June 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on May 13th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 7/1/2025.
• Purchased $1,001 - $15,000 in shares of AppLovin NASDAQ: APP on 7/1/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 6/30/2025.
• Purchased $1,001 - $15,000 in shares of CoStar Group NASDAQ: CSGP on 6/30/2025.
• Purchased $15,001 - $50,000 in shares of CoStar Group NASDAQ: CSGP on 6/27/2025.
• Purchased $1,001 - $15,000 in shares of Xiaomi OTCMKTS: XIACF on 6/27/2025.
• Sold $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 6/27/2025.
• Sold $1,001 - $15,000 in shares of Willis Towers Watson Public NASDAQ: WTW on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Boston Scientific NYSE: BSX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Liberty Media Corporation - Liberty Formula One Series C NASDAQ: FWONK on 6/26/2025.

Boston Scientific Stock Down 0.1%

NYSE:BSX traded down $0.14 during trading hours on Friday, reaching $106.07. The company's stock had a trading volume of 5,875,124 shares, compared to its average volume of 7,847,640. Boston Scientific Corporation has a one year low of $71.88 and a one year high of $108.94. The business's 50-day moving average is $103.58 and its 200-day moving average is $101.51. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. The company has a market cap of $156.92 billion, a price-to-earnings ratio of 63.14, a price-to-earnings-growth ratio of 2.67 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.39% and a net margin of 13.55%. The firm's revenue was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 earnings per share. Equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Institutional Trading of Boston Scientific

Several hedge funds have recently added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund raised its position in shares of Boston Scientific by 0.9% in the second quarter. Oregon Public Employees Retirement Fund now owns 127,839 shares of the medical equipment provider's stock valued at $13,731,000 after purchasing an additional 1,200 shares during the period. Sequoia Financial Advisors LLC grew its stake in Boston Scientific by 6.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 40,748 shares of the medical equipment provider's stock worth $4,377,000 after buying an additional 2,293 shares in the last quarter. Welch Group LLC grew its stake in Boston Scientific by 3.5% in the 2nd quarter. Welch Group LLC now owns 4,641 shares of the medical equipment provider's stock worth $498,000 after buying an additional 159 shares in the last quarter. Clarendon Private LLC grew its stake in Boston Scientific by 11.5% in the 2nd quarter. Clarendon Private LLC now owns 10,046 shares of the medical equipment provider's stock worth $1,079,000 after buying an additional 1,037 shares in the last quarter. Finally, CWM LLC grew its stake in Boston Scientific by 36.9% in the 2nd quarter. CWM LLC now owns 51,316 shares of the medical equipment provider's stock worth $5,512,000 after buying an additional 13,840 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on BSX. Oppenheimer lifted their target price on Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a research report on Thursday. Truist Financial raised their target price on Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday. Robert W. Baird boosted their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday. Citigroup reaffirmed a "buy" rating and set a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a report on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $117.50.

Insider Activity

In related news, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total value of $17,051,094.67. Following the transaction, the chief executive officer owned 1,476,882 shares of the company's stock, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the sale, the executive vice president owned 22,235 shares in the company, valued at approximately $2,269,304.10. The trade was a 43.78% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 457,144 shares of company stock worth $47,296,288. 0.50% of the stock is currently owned by corporate insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.